$ALLO
Allogene Therapeutics, Inc.

2020 Q4 Form 10-Q Financial Statement

#000173728720000059 Filed on November 04, 2020

View on sec.gov

Income Statement

Concept 2020 Q4 2020 Q3 2019 Q3
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $17.13M $16.62M $15.02M
YoY Change 12.62% 10.65% 59.45%
% of Gross Profit
Research & Development $52.23M $51.42M $40.00M
YoY Change 4.96% 28.57% 267.94%
% of Gross Profit
Depreciation & Amortization $1.850M $1.810M $1.330M
YoY Change 0.0% 36.09% 166.0%
% of Gross Profit
Operating Expenses $69.36M $68.04M $55.01M
YoY Change 6.74% 23.68% 147.94%
Operating Profit -$68.04M -$55.01M
YoY Change 23.68% 147.94%
Interest Expense $1.560M $2.010M $0.00
YoY Change -57.38% -100.0%
% of Operating Profit
Other Income/Expense, Net -$770.0K $1.843M $4.309M
YoY Change 185.19% -57.23% -120.22%
Pretax Income -$68.57M -$66.20M -$50.70M
YoY Change 12.06% 30.56% 16.56%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$68.57M -$66.20M -$50.74M
YoY Change 12.35% 30.48% 16.64%
Net Earnings / Revenue
Basic Earnings Per Share -$0.52
Diluted Earnings Per Share -$528.3K -$0.52 -$496.5K
COMMON SHARES
Basic Shares Outstanding 140.3M shares 127.1M shares 121.7M shares
Diluted Shares Outstanding 127.1M shares

Balance Sheet

Concept 2020 Q4 2020 Q3 2019 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $827.9M $841.0M $501.2M
YoY Change 56.05% 67.79% 105.26%
Cash & Equivalents $183.4M $158.1M $161.0M
Short-Term Investments $644.6M $682.9M $340.3M
Other Short-Term Assets $17.20M $13.00M $6.200M
YoY Change 48.28% 109.68% 100.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $845.1M $854.1M $509.8M
YoY Change 55.19% 67.54% 106.08%
LONG-TERM ASSETS
Property, Plant & Equipment $118.8M $102.7M $45.94M
YoY Change 110.53% 123.44% 878.97%
Goodwill
YoY Change
Intangibles $0.00 $0.00 $301.0K
YoY Change -100.0% -100.0% -66.7%
Long-Term Investments $207.9M $212.5M $100.7M
YoY Change 228.96% 111.02% -34.61%
Other Assets $5.169M $2.274M $3.105M
YoY Change 11.93% -26.76% 34.59%
Total Long-Term Assets $382.7M $368.4M $185.8M
YoY Change 120.92% 98.31% -1.12%
TOTAL ASSETS
Total Short-Term Assets $845.1M $854.1M $509.8M
Total Long-Term Assets $382.7M $368.4M $185.8M
Total Assets $1.228B $1.223B $695.5M
YoY Change 71.05% 75.76% 59.81%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $10.39M $10.15M $8.047M
YoY Change 12.32% 26.15% 161.01%
Accrued Expenses $44.90M $40.00M $25.30M
YoY Change 88.66% 58.1% 50.6%
Deferred Revenue $38.99M
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change -100.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $94.32M $50.13M $33.35M
YoY Change 185.14% 50.3% -79.09%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $3.083M $2.793M $4.785M
YoY Change -29.14% -41.63% -36.1%
Total Long-Term Liabilities $3.083M $2.793M $4.785M
YoY Change -29.14% -41.63% -36.1%
TOTAL LIABILITIES
Total Short-Term Liabilities $94.32M $50.13M $33.35M
Total Long-Term Liabilities $3.083M $2.793M $4.785M
Total Liabilities $148.2M $103.8M $75.83M
YoY Change 66.94% 36.85% -60.63%
SHAREHOLDERS EQUITY
Retained Earnings -$646.3M -$577.8M -$335.1M
YoY Change 63.17% 72.43% 85.12%
Common Stock $1.726B $1.696B $952.9M
YoY Change 68.52% 77.93% 7389.33%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $1.080B $1.119B $619.7M
YoY Change
Total Liabilities & Shareholders Equity $1.228B $1.223B $695.5M
YoY Change 71.05% 75.76% 59.81%

Cashflow Statement

Concept 2020 Q4 2020 Q3 2019 Q3
OPERATING ACTIVITIES
Net Income -$68.57M -$66.20M -$50.74M
YoY Change 12.35% 30.48% 16.64%
Depreciation, Depletion And Amortization $1.850M $1.810M $1.330M
YoY Change 0.0% 36.09% 166.0%
Cash From Operating Activities -$9.970M -$37.59M -$31.93M
YoY Change -80.17% 17.73% 86.4%
INVESTING ACTIVITIES
Capital Expenditures -$17.41M -$20.24M -$18.40M
YoY Change 23.39% 10.0% 1243.07%
Acquisitions
YoY Change
Other Investing Activities $39.61M -$63.11M $97.17M
YoY Change 79.64% -164.95% -130.81%
Cash From Investing Activities $22.21M -$83.35M $78.78M
YoY Change 180.43% -205.8% -124.87%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 12.98M 3.850M 1.570M
YoY Change -77.01% 145.22% -99.43%
NET CHANGE
Cash From Operating Activities -9.970M -37.59M -31.93M
Cash From Investing Activities 22.21M -83.35M 78.78M
Cash From Financing Activities 12.98M 3.850M 1.570M
Net Change In Cash 25.22M -117.1M 48.42M
YoY Change 78.61% -341.82% -180.9%
FREE CASH FLOW
Cash From Operating Activities -$9.970M -$37.59M -$31.93M
Capital Expenditures -$17.41M -$20.24M -$18.40M
Free Cash Flow $7.440M -$17.35M -$13.53M
YoY Change -120.58% 28.23% -14.15%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Amendment Flag
AmendmentFlag
false
dei Amendment Flag
AmendmentFlag
false
dei Entity Central Index Key
EntityCentralIndexKey
0001737287
dei Entity Central Index Key
EntityCentralIndexKey
0001737287
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2020
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2020
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
CY2019Q4 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
allo:AccruedAndOtherLiabilitiesCurrent
CY2020Q3 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
allo:AccruedAndOtherLiabilitiesCurrent
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2020-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity Shell Company
EntityShellCompany
false
dei Entity File Number
EntityFileNumber
001-38693
dei Entity Registrant Name
EntityRegistrantName
Allogene Therapeutics, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
82-3562771
dei Entity Address Address Line1
EntityAddressAddressLine1
210 East Grand Avenue
dei Entity Address City Or Town
EntityAddressCityOrTown
South San Francisco
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94080
dei City Area Code
CityAreaCode
650
dei Local Phone Number
LocalPhoneNumber
457-2700
dei Security12b Title
Security12bTitle
Common Stock, $0.001 par value per share
dei Trading Symbol
TradingSymbol
ALLO
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2020Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
140280152 shares
CY2020Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
158136000 USD
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
175126000 USD
CY2020Q3 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
682886000 USD
CY2019Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
355407000 USD
CY2020Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
13036000 USD
CY2019Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
14043000 USD
CY2020Q3 us-gaap Assets Current
AssetsCurrent
854058000 USD
CY2019Q4 us-gaap Assets Current
AssetsCurrent
544576000 USD
CY2020Q3 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
207993000 USD
CY2019Q4 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
58322000 USD
CY2020Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
41557000 USD
CY2019Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
44495000 USD
CY2020Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
102653000 USD
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
56449000 USD
CY2020Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
0 USD
CY2019Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
151000 USD
CY2020Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
9449000 USD
CY2019Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
4299000 USD
CY2020Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
2274000 USD
CY2019Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
4618000 USD
CY2020Q3 us-gaap Investments In Affiliates Subsidiaries Associates And Joint Ventures
InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures
4516000 USD
CY2019Q4 us-gaap Investments In Affiliates Subsidiaries Associates And Joint Ventures
InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures
4892000 USD
CY2020Q3 us-gaap Assets
Assets
1222500000 USD
CY2019Q4 us-gaap Assets
Assets
717802000 USD
CY2020Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
10151000 USD
CY2019Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
9250000 USD
CY2020Q3 allo Accrued And Other Liabilities Current
AccruedAndOtherLiabilitiesCurrent
39979000 USD
CY2019Q4 allo Accrued And Other Liabilities Current
AccruedAndOtherLiabilitiesCurrent
23829000 USD
CY2020Q3 us-gaap Liabilities Current
LiabilitiesCurrent
50130000 USD
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
33079000 USD
CY2020Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
50846000 USD
CY2019Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
51349000 USD
CY2020Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
2793000 USD
CY2019Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
4351000 USD
CY2020Q3 us-gaap Liabilities
Liabilities
103769000 USD
CY2019Q4 us-gaap Liabilities
Liabilities
88779000 USD
CY2020Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2019Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2019Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2020Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2019Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2020Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2020Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2019Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2020Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2019Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2020Q3 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2019Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2020Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2020Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
139755839 shares
CY2020Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
139755839 shares
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
124267358 shares
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
124267358 shares
CY2020Q3 us-gaap Common Stock Value
CommonStockValue
140000 USD
CY2019Q4 us-gaap Common Stock Value
CommonStockValue
124000 USD
CY2020Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1695411000 USD
CY2019Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1023876000 USD
CY2020Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-577773000 USD
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-396122000 USD
CY2020Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1222500000 USD
CY2020Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
953000 USD
CY2019Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
1145000 USD
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
1118731000 USD
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
629023000 USD
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
717802000 USD
CY2020Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
51421000 USD
CY2019Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
39995000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
140759000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
95172000 USD
CY2020Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
16619000 USD
CY2019Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
15016000 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
48122000 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
42261000 USD
CY2020Q3 us-gaap Operating Expenses
OperatingExpenses
68040000 USD
CY2019Q3 us-gaap Operating Expenses
OperatingExpenses
55011000 USD
us-gaap Operating Expenses
OperatingExpenses
188881000 USD
us-gaap Operating Expenses
OperatingExpenses
137433000 USD
CY2020Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-68040000 USD
CY2019Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-55011000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-188881000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-137433000 USD
CY2020Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
2005000 USD
CY2019Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
4309000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
7606000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
13693000 USD
CY2020Q3 us-gaap Other Expenses
OtherExpenses
162000 USD
CY2019Q3 us-gaap Other Expenses
OtherExpenses
0 USD
us-gaap Other Expenses
OtherExpenses
376000 USD
us-gaap Other Expenses
OtherExpenses
0 USD
CY2020Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1843000 USD
CY2019Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
4309000 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
7230000 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
13693000 USD
CY2020Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-66197000 USD
CY2019Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-50702000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-181651000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-123740000 USD
CY2020Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
CY2019Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
33000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-176000 USD
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-66197000 USD
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
-50735000 USD
us-gaap Net Income Loss
NetIncomeLoss
-181651000 USD
us-gaap Net Income Loss
NetIncomeLoss
-123564000 USD
CY2020Q3 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-877000 USD
CY2019Q3 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-295000 USD
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-192000 USD
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
1560000 USD
CY2019Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-51030000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-181843000 USD
CY2020Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-67074000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-122004000 USD
CY2020Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.52
CY2019Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.50
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.55
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.24
CY2020Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
127140755 shares
CY2019Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
102186644 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
117227079 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
99801001 shares
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
1163419000 USD
CY2020Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
2447000 USD
CY2020Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
710000 USD
CY2020Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
17823000 USD
CY2020Q3 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
1406000 USD
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-66197000 USD
CY2020Q3 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-877000 USD
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
1118731000 USD
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
629023000 USD
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
7227000 USD
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
2130000 USD
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
48808000 USD
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
2843000 USD
us-gaap Net Income Loss
NetIncomeLoss
-181651000 USD
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-192000 USD
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
1118731000 USD
CY2019Q2 us-gaap Stockholders Equity
StockholdersEquity
655635000 USD
CY2019Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
467000 USD
CY2019Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
710000 USD
CY2019Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
12835000 USD
CY2019Q3 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
1099000 USD
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
-50735000 USD
CY2019Q3 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-295000 USD
CY2019Q3 us-gaap Stockholders Equity
StockholdersEquity
619716000 USD
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
703164000 USD
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
704000 USD
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
3880000 USD
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
32189000 USD
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
1783000 USD
us-gaap Net Income Loss
NetIncomeLoss
-123564000 USD
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
1560000 USD
CY2019Q3 us-gaap Stockholders Equity
StockholdersEquity
619716000 USD
us-gaap Profit Loss
ProfitLoss
-181651000 USD
us-gaap Profit Loss
ProfitLoss
-123564000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
48808000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
32189000 USD
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
151000 USD
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
452000 USD
us-gaap Depreciation
Depreciation
5591000 USD
us-gaap Depreciation
Depreciation
2720000 USD
us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
-1437000 USD
us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
3136000 USD
us-gaap Operating Lease Expense
OperatingLeaseExpense
1240000 USD
us-gaap Operating Lease Expense
OperatingLeaseExpense
4827000 USD
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
0 USD
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-176000 USD
allo Income Loss From Cost Method Investment
IncomeLossFromCostMethodInvestment
-376000 USD
allo Income Loss From Cost Method Investment
IncomeLossFromCostMethodInvestment
0 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-657000 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-86000 USD
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-1975000 USD
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
2863000 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1681000 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-3137000 USD
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
16175000 USD
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
7510000 USD
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-1558000 USD
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-1991000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-105118000 USD
us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
4877000 USD
us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
0 USD
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
371777000 USD
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
355765000 USD
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
855433000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-87083000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
48554000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
36679000 USD
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
162931000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-527333000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
156155000 USD
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
7194000 USD
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
703000 USD
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
2844000 USD
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
1783000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
620613000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
2486000 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-11838000 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
71558000 USD
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
179425000 USD
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
93731000 USD
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
167587000 USD
CY2019Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
165289000 USD
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
7909000 USD
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
6571000 USD
us-gaap Payments For Leasing Costs Commissions And Tenant Improvements
PaymentsForLeasingCostsCommissionsAndTenantImprovements
4236000 USD
us-gaap Payments For Leasing Costs Commissions And Tenant Improvements
PaymentsForLeasingCostsCommissionsAndTenantImprovements
2182000 USD
allo Cash Received For Amounts Related To Tenant Improvement Allowances
CashReceivedForAmountsRelatedToTenantImprovementAllowances
2321000 USD
allo Cash Received For Amounts Related To Tenant Improvement Allowances
CashReceivedForAmountsRelatedToTenantImprovementAllowances
2934000 USD
us-gaap Nature Of Operations
NatureOfOperations
Description of Business<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Allogene Therapeutics, Inc. (the Company or Allogene) was incorporated on November 30, 2017, in the State of Delaware and is headquartered in South San Francisco, California. Allogene is a clinical-stage immuno-oncology company pioneering the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The Company is developing a pipeline of off-the-shelf T cell product candidates that are designed to target and kill cancer cells.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Public Offerings </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In November 2019, the Company entered into a sales agreement with Cowen and Company, LLC (Cowen), under which the Company may from time to time issue and sell shares of its common stock through Cowen in at-the-market (ATM) offerings for an aggregate offering price of up to $250.0 million. The aggregate compensation payable to Cowen as the Company's sales agent equals up to 3.0% of the gross sales price of the shares sold through it pursuant to the sales agreement. In January 2020, the Company sold an aggregate of 570,839 shares of common stock in ATM offerings resulting in net proceeds of $14.8 million.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In June 2020, the Company sold 13,457,447 shares of its common stock, which included 1,755,319 shares sold pursuant to the full exercise of the underwriters' option to purchase additional shares, in an underwritten public offering at a price of $47.00 per share, which resulted in gross proceeds of approximately $632.5 million. Net proceeds to the Company after deducting the underwriting discounts and commissions and other expenses were approximately $595.7 million.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Need for Additional Capital</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has sustained operating losses and expects to continue to generate operating losses for the foreseeable future. The Company’s ultimate success depends on the outcome of its research and development activities. The Company had cash and cash equivalents and investments of $1.0 billion as of September 30, 2020. Since inception through September 30, 2020, the Company has incurred cumulative net losses of $577.8 million. Management expects to incur additional losses in the future to fund its operations and conduct product research and development and recognizes the need to raise additional capital to fully implement its business plan.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company intends to raise additional capital through the issuance of equity securities, debt financings or other sources in order to further implement its business plan. However, if such financing is not available when needed and at adequate levels, the Company will need to reevaluate its operating plan and may be required to delay the development of its product candidates. The Company expects that its cash and cash equivalents and investments will be sufficient to fund its operations for a period of at least one year from the date the accompanying unaudited condensed consolidated financial statements are filed with the Securities and Exchange Commission (SEC). </span></div>In March 2020, the World Health Organization declared the global novel coronavirus disease (COVID-19) outbreak a pandemic. The Company cannot at this time predict the specific extent, duration, or full impact that the COVID-19 pandemic will have on its financial condition and operations, including ongoing and planned clinical trials. The impact of the COVID-19 pandemic on the financial performance of the Company will depend on future developments, including the duration and spread of the pandemic and related governmental advisories and restrictions. These developments and the impact of the COVID-19 pandemic on the financial markets and the overall economy are highly uncertain. If the financial markets and/or the overall economy are impacted for an extended period, the Company’s results may be adversely affected.
CY2019Q4 allo Stock Issuance Maximum Value
StockIssuanceMaximumValue
250000000.0 USD
CY2019Q4 allo Stock Issuance Maximum Compensation Due To Third Party Percent
StockIssuanceMaximumCompensationDueToThirdPartyPercent
0.030
CY2020Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
570839 shares
CY2020Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
14800000 USD
CY2020Q2 us-gaap Sale Of Stock Number Of Shares Issued In Transaction
SaleOfStockNumberOfSharesIssuedInTransaction
13457447 shares
CY2020Q2 us-gaap Sale Of Stock Price Per Share
SaleOfStockPricePerShare
47.00
CY2020Q2 us-gaap Sale Of Stock Consideration Received On Transaction
SaleOfStockConsiderationReceivedOnTransaction
632500000 USD
CY2020Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
595700000 USD
CY2020Q3 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
1000000000.0 USD
CY2020Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-577800000 USD
us-gaap Use Of Estimates
UseOfEstimates
<div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the consolidated financial statements and the reported amounts of expenses during the reporting period. Significant estimates and assumptions made in the accompanying condensed consolidated financial statements include but are not limited to the fair value of stock options, income tax uncertainties, and certain accruals. The Company evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances dictate. Actual results could differ from those estimates.</span></div>
CY2020Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
CY2019Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-200000 USD
CY2020Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
990548000 USD
CY2020Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
1444000 USD
CY2020Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
48000 USD
CY2020Q3 allo Cash Equivalents And Short Term Investments
CashEquivalentsAndShortTermInvestments
991944000 USD
CY2020Q3 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
101065000 USD
CY2020Q3 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
682886000 USD
CY2020Q3 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
207993000 USD
CY2020Q3 allo Cash Equivalents And Short Term Investments
CashEquivalentsAndShortTermInvestments
991944000 USD
CY2019Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
535042000 USD
CY2019Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
1595000 USD
CY2019Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
8000 USD
CY2019Q4 allo Cash Equivalents And Short Term Investments
CashEquivalentsAndShortTermInvestments
536629000 USD
CY2019Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
122900000 USD
CY2019Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
355407000 USD
CY2019Q4 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
58322000 USD
CY2019Q4 allo Cash Equivalents And Short Term Investments
CashEquivalentsAndShortTermInvestments
536629000 USD
CY2020Q3 us-gaap Debt Securities Available For Sale Term
DebtSecuritiesAvailableForSaleTerm
P3Y
CY2019Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
5472000 USD
CY2020Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
102653000 USD
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
56449000 USD
CY2020Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
113716000 USD
CY2019Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
61921000 USD
CY2020Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
11063000 USD
CY2018Q3 allo Area Of New Office Building
AreaOfNewOfficeBuilding
68000 sqft
CY2018Q3 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P127M
CY2018Q3 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P7Y
CY2020Q3 us-gaap Tenant Improvements
TenantImprovements
5000000.0 USD
CY2018Q4 allo Area Of New Office Building
AreaOfNewOfficeBuilding
14943 sqft
CY2018Q4 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P124M
CY2018Q4 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P7Y
CY2018Q4 allo Allowance For Tenant Improvements
AllowanceForTenantImprovements
800000 USD
CY2020Q3 us-gaap Letters Of Credit Outstanding Amount
LettersOfCreditOutstandingAmount
5200000 USD
CY2019Q4 us-gaap Letters Of Credit Outstanding Amount
LettersOfCreditOutstandingAmount
4300000 USD
CY2020Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
50846000 USD
CY2019Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
51349000 USD
CY2020Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
53719000 USD
CY2020Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2873000 USD
CY2019Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1679000 USD
CY2019Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
53028000 USD
CY2020Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
1845000 USD
CY2019Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
1374000 USD
us-gaap Operating Lease Cost
OperatingLeaseCost
5543000 USD
us-gaap Operating Lease Cost
OperatingLeaseCost
4076000 USD
CY2020Q3 us-gaap Variable Lease Cost
VariableLeaseCost
353000 USD
CY2019Q3 us-gaap Variable Lease Cost
VariableLeaseCost
277000 USD
us-gaap Variable Lease Cost
VariableLeaseCost
961000 USD
us-gaap Variable Lease Cost
VariableLeaseCost
702000 USD
CY2020Q3 us-gaap Lease Cost
LeaseCost
2198000 USD
CY2019Q3 us-gaap Lease Cost
LeaseCost
1651000 USD
us-gaap Lease Cost
LeaseCost
6504000 USD
us-gaap Lease Cost
LeaseCost
4778000 USD
us-gaap Operating Lease Payments
OperatingLeasePayments
4200000 USD
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
1426000 USD
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
6649000 USD
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
7922000 USD
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
8173000 USD
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
8435000 USD
CY2020Q3 allo Lessee Operating Lease Liability Payments Due After Year Four
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour
56722000 USD
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
89327000 USD
CY2020Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
33496000 USD
CY2020Q3 allo Allowance For Tenant Improvements
AllowanceForTenantImprovements
2112000 USD
CY2020Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
53719000 USD
CY2020Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0836
CY2020Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P10Y4M28D
CY2020Q3 us-gaap Purchase Commitment Remaining Minimum Amount Committed
PurchaseCommitmentRemainingMinimumAmountCommitted
3900000 USD
allo Number Of Shares As Percentage Of Common Shares Outstanding
NumberOfSharesAsPercentageOfCommonSharesOutstanding
0.05
CY2020Q3 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
12321515 shares
CY2020Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
17823000 USD
CY2019Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
12834000 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
48808000 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
32189000 USD
CY2020Q3 us-gaap Deferred Compensation Share Based Arrangements Liability Current
DeferredCompensationShareBasedArrangementsLiabilityCurrent
2800000 USD
CY2019Q4 us-gaap Deferred Compensation Share Based Arrangements Liability Current
DeferredCompensationShareBasedArrangementsLiabilityCurrent
2800000 USD
CY2020Q3 us-gaap Deferred Compensation Sharebased Arrangements Liability Classified Noncurrent
DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent
1800000 USD
CY2019Q4 us-gaap Deferred Compensation Sharebased Arrangements Liability Classified Noncurrent
DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent
3900000 USD
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
24638212 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
29878302 shares
CY2020Q3 us-gaap Purchase Commitment Remaining Minimum Amount Committed
PurchaseCommitmentRemainingMinimumAmountCommitted
3900000 USD

Files In Submission

Name View Source Status
0001737287-20-000059-index-headers.html Edgar Link pending
0001737287-20-000059-index.html Edgar Link pending
0001737287-20-000059.txt Edgar Link pending
0001737287-20-000059-xbrl.zip Edgar Link pending
allo-20200930.htm Edgar Link pending
allo-20200930.xsd Edgar Link pending
allo-20200930xex311.htm Edgar Link pending
allo-20200930xex312.htm Edgar Link pending
allo-20200930xex321.htm Edgar Link pending
allo-20200930_cal.xml Edgar Link unprocessable
allo-20200930_def.xml Edgar Link unprocessable
allo-20200930_htm.xml Edgar Link completed
allo-20200930_lab.xml Edgar Link unprocessable
allo-20200930_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending